Form 4: GTHP Director Boosts Stake via Conversions & Options

A director and 10% owner of Guided Therapeutics Inc. significantly increased common stock holdings through preferred stock dividend conversions and a direct preferred stock conversion, alongside receiving new stock options.

Summary

• Richard P. Blumberg, a Director and 10% Owner of Guided Therapeutics Inc. (GTHP), reported several transactions increasing his beneficial ownership of common stock.
• On April 10, 2025, he acquired 165,481 shares of common stock from the payment of accrued dividends on Series F preferred stock, at a conversion price of $0.0943 per share.
• Also on April 10, 2025, he acquired an additional 55,853 shares of common stock from the payment of accrued dividends on Series F-2 preferred stock, at a conversion price of $0.0943 per share.
• On August 21, 2025, he acquired 81,121 shares of common stock from the payment of accrued dividends on Series E preferred stock, at a conversion price of $0.2298 per share.
• On August 21, 2025, Mr. Blumberg, through the WMB Pension Plan fbo Richard Blumberg, converted 233 shares of Series E preferred stock (stated value $1,000 each, $0.25 exercise price) into 932,000 shares of common stock, resulting in zero Series E preferred stock beneficially owned.
• Following these transactions, his direct beneficial ownership of common stock increased to 7,924,180 shares.
• Additionally, on June 3, 2025, Mr. Blumberg was granted 110,000 stock options with an exercise price of $0.14. One-fourth of these options vested on June 3, 2025, with the remainder vesting monthly starting September 3, 2025, until fully vested on June 2, 2028.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. Increased insider ownership, especially by a director and 10% owner, through conversions and option grants, generally signals confidence in the company's future prospects and aligns management's interests with shareholders. However, a Form 4 alone does not provide a comprehensive financial picture.

Positives

• Increased beneficial ownership of common stock by a director and 10% owner, signaling confidence in the company.
• Conversion of preferred stock into common stock, simplifying the capital structure for the reporting person.
• Grant of new stock options aligns the director's incentives with long-term shareholder value.

Future Outlook

The granted stock options will vest over time, with one-fourth vesting on June 3, 2025, and the remaining shares vesting monthly starting September 3, 2025, until fully vested on June 2, 2028, subject to continued service.

Industry Context

This Form 4 filing details specific insider transactions for Guided Therapeutics Inc. and does not provide broader industry trends or competitive analysis. It reflects an individual director's investment activity within the company.

Stakeholder Impact

• Shareholders: Increased alignment of a key director and 10% owner with shareholder interests through greater common stock ownership and long-term option incentives.
• Employees: The vesting schedule of options is tied to the reporting person's continued service, which can imply stability in leadership.

Next Steps

• Continued monthly vesting of stock options for Richard P. Blumberg, starting September 3, 2025, until full vesting on June 2, 2028.

Key Dates

Recommendation

The increase in beneficial ownership by a director and 10% owner, primarily through conversions of preferred stock and dividend payments into common stock, along with a new stock option grant, generally signals confidence in the company's future. However, a Form 4 filing alone does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. Investors should consider this as a positive signal but conduct further due diligence on the company's fundamentals before making investment decisions.

Keywords

GUIDED THERAPEUTICS INC, GTHP, Richard P. Blumberg, Insider Trading, Form 4, Stock Options, Preferred Stock Conversion, Beneficial Ownership, Director Transactions, Equity Acquisition